Navigation Links
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  A press release will be issued prior to the call.

Teleconference/Webcast Details To participate in the live call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 33105543.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com.  The webcast will be available for 30 days following the call.About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Christine A. Poon Elected to Regeneron Board of Directors
2. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
3. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
4. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
5. Regeneron Increases Size of Public Offering of Common Stock
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
8. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
11. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the Cowen and Company 37 th Annual Health ... Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/cowen38/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... , Australien, 24. Februar 2017 ... diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für das ... mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu ... und Aktualisierung zum Wachstum" finden Sie hier ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Healthcare Associates ... Medical Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, ... with easy access to Highway 121. , As the practice has grown, the need ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... present generation. Yisrayl makes an astounding statement when he says that the entire ... the Bible details the current times so plainly that anyone should be able to ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
Breaking Medicine News(10 mins):